Overview
NICE is unable to make a recommendation on sirolimus (Hyftor) for treating facial angiofibroma caused by tuberous sclerosis complex in people 6 years and over. This is because Plusultra pharma did not provide an adequate evidence submission for committee decision-making.
Last reviewed: 27 January 2026
This guidance was updated to reflect that a review of this guidance was also terminated.
Next review: We will review this decision if the company decides to make a submission.